Akebia Therapeutics, Inc.

Akebia Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for patients with kidney disease. It leverages its expertise in kidney disease biology to advance its pipeline of innovative therapies aimed at treating conditions such as chronic kidney disease (CKD). The company's lead product, vadadustat, is designed to simulate the body's response to reduced oxygen levels, providing an oral treatment for anemia due to CKD. Akebia's operations encompass both the development and partnership aspects, collaborating with academic institutions and pharmaceutical companies to maximize the impact of its therapies. Headquartered in Cambridge, Massachusetts, Akebia plays a significant role in the healthcare sector by addressing unmet medical needs in nephrology. The company's commitment to improving patient lives through scientific innovation positions it as a significant player in the biopharmaceutical landscape.